Parkinson’s Disease Treatment Market to Reach USD 19.24 Billion by 2035

According to analysts at Vantage Market Research, the Global Parkinson’s Disease Treatment Market size is worth USD 6.67 Billion in 2024 and is projected to reach USD 19.24 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 10.1% from 2024 to 2035. Key trends of market the growing adoption of advanced therapies like deep brain stimulation, dopamine agonists, personalized treatments, and ongoing research into disease-modifying treatments and growing elderly population.

Market Overview

The treatment for Parkinson’s disease (PD) is evolving with the development of novel therapies that aim to improve patient outcomes. Traditional treatments, such as Carbidopa-Levodopa, primarily focus on symptom management rather than slowing disease progression. However, disease-modifying therapies are emerging, aiming to address the root causes of PD, such as the accumulation of alpha-synuclein proteins in the brain. These innovative therapies, along with new drug delivery systems like continuous infusion therapies or extended-release formulations, are providing more effective and sustained symptom control. 

Gene therapy and personalized medicine are rapidly emerging as transformative approaches to treating Parkinson’s disease in Parkinson’s Disease Treatment market. Gene therapy involves delivering specific genes into a patient’s cells to correct or replace faulty genes that contribute to the disease, potentially modifying the disease’s course. This approach is particularly exciting for PD, as it targets the underlying mechanisms of the disease rather than just alleviating symptoms. Personalized medicine tailors’ treatments to individual patients based on their genetic makeup, lifestyle, and other factors, ensuring more effective and less risky treatments. 

AbbVie's VYALEV Gains FDA Approval as First 24-Hour Levodopa Infusion Therapy for Parkinson's

• In October 2024, AbbVie announced FDA approval for VYALEV (foscarbidopa/foslevodopa), a groundbreaking treatment for motor fluctuations in adults with advanced Parkinson's disease. This therapy is the first of its kind to provide a 24-hour continuous subcutaneous infusion of a levodopa-based medication

Key Takeaways from the Report

• In 2024, North America dominated the market with 38.3% share. Market is driven by the presence of major companies like AbbVie Inc., Merck & Co. Inc., Amneal Pharmaceuticals LLC, and Sunovion Pharmaceuticals Inc
• In 2024, Based on the Drug Class, the Carbidopa-levodopa category accounted for significant market share of 23.7%. The segment is driven by due to the high prescription rate of medications
• In 2024, by Distribution Channel, Retail Pharmacy dominated the market share of 60.1%. The widespread availability of PD drugs, including generic options like carbidopa-levodopa, pramipexole dihydrochloride in retail pharmacies

Top Companies

• Cerevel Therapeutics
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• GlaxoSmithKline plc. (GSK)
• AbbVie Inc., H. Lundbeck A/S
• Amneal Pharmaceuticals LLC
• Supernus Pharmaceuticals Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Sunbird Bio Unveils Diagnostic Breakthrough for Parkinson's Disease with 86% Accuracy

• In November 2024, Sunbird Bio unveiled new findings demonstrating that its diagnostic technology achieved an 86% accuracy rate in classifying blood samples from patients with Parkinson's disease by directly detecting aggregated alpha-synuclein proteins